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1 |  INTRODUCTION
The clinical consequences of isolated decreased serum immu-
noglobulin (Ig)M levels are not sufficiently known. Clinicians 
struggle with what they should do with such a finding. IgM 
deficiency has mainly been studied in tertiary centre cohorts, 
where a variety of clinical manifestations have been linked 
with decreased serum IgM levels, including severe or recur-
rent infections, atopy, autoimmunity and malignancy.1 Only 
small cohorts of IgM‐deficient patients have been described 
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Abstract
The clinical consequences of isolated decreased serum immunoglobulin (Ig)M are 
not sufficiently known. Therefore, it is difficult to determine the clinical policy fol-
lowing such a finding. Only few reported IgM‐deficient patients fulfil the European 
Society for Immunodeficiencies (ESID) diagnostic criteria for selective IgM defi-
ciency (true sIgMdef), or their diagnosis is uncertain due to insufficient laboratory 
data (possible sIgMdef). Decreased serum IgM is often incidentally found in asymp-
tomatic adults. The objective of our study was to further characterize true sIgMdef 
and to compare the European data collected through the ESID Registry community 
(tertiary centres) to our previously published Dutch cohort (secondary centre). 
Fifteen centres (12 countries) participated with 98 patients. Patients were excluded if 
serum IgM was only determined once (n = 14), had normalized (n = 8), or if they 
also had other immunological abnormalities (n = 15). Ten patients (5 adults) com-
pletely fulfilled the ESID criteria for true sIgMdef. Age‐matched cut‐off values var-
ied widely between centres; when using the ESID diagnostic protocol reference 
values, only six patients (five adults) had true sIgMdef. Because of these small num-
bers, further analyses were performed in patients with true or possible sIgMdef (13 
adults, 48 children). Respiratory infections were commonly reported at presentation 
(adults 54%, children 60%). Symptomatic adults had lower serum IgM levels (mean 
0.27 g/L, 95% CI 0.22‐0.31) than those without symptoms (mean 0.33 g/L, 95% CI 
0.30‐0.36; P = 0.02). To be able to explore the clinical consequences of true sIgM-
def, we should fully analyse and accurately describe those patients in whom a 
decreased serum IgM is found.
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so far.2,3 In 2006, the largest study to date was published, 
reporting data from 36 patients.14 The reported patients are 
almost always symptomatic and most of them presented with 
infections.1 We recently showed in a secondary centre popu-
lation that decreased serum IgM levels can often incidentally 
be found in asymptomatic adults.15 The determination of the 
clinical significance of sIgMdef is not only challenged by the 
rarity and highly variable phenotype of this primary immuno-
deficiency, but also by the different criteria for “selective IgM 
deficiency” that are used in the literature.5,6,14,16 ESID has 
defined primary selective immunoglobulin(Ig)M deficiency 
(sIgMdef) as a decreased serum IgM level (repeatedly ≥ 2 
SD below the mean for age) with normal levels of serum 
IgA, IgG and IgG subclasses, normal vaccination responses, 
absence of T cell defects and absence of causative external 
factors (http://www.esid.org). When these criteria are com-
pletely fulfilled, we refer to this condition as “truly selective 
primary IgM deficiency” (true sIgMdef), albeit we consider 
the absence of clinical signs suggesting a T cell defect a suf-
ficient criterion. Only six of 261 (2%) patients described in 
the literature with “IgM deficiency” completely fulfil the de-
fined criteria for true sIgMdef.15 For many reported patients, 
the diagnosis is either uncertain, which means that the ESID 
criteria are not fulfilled completely because data on IgG sub-
classes and/or vaccination responses are lacking (we refer to 
the latter as “possible sIgMdef”),15 or their IgM deficiency 
is not selective, because other antibody abnormalities are 
present; these cases fit the ESID classification “unclassified 
primary antibody deficiency” (unPAD).3,6,17
A larger cohort of true sIgMdef patients is needed to fur-
ther explore the clinical consequences. Therefore, we initi-
ated this multi‐centre observational cohort study using the 
ESID online database. We also compared these European 
data (tertiary centres) to our previously published Dutch co-
hort (secondary centre).15
2 |  MATERIALS AND METHODS
2.1 | Patient identification and recruitment
Email messages with the proposal to participate in the 
SIMcal study were sent out to all members of ESID to iden-
tify as many patients known to ESID members as possible 
with sIgMdef. Fifteen centres agreed to participate. Of these, 
11 centres had registered their patients in the ESID online 
database.18 The four centres not connected to the ESID online 
database also joined the SIMcal study. All patients docu-
mented by the participating centres to have sIgMdef were 
eligible for analysis. Only the patients with possible and true 
primary sIgMdef were analysed in detail (for definitions, see 
introduction). In all cases, patients had given informed con-
sent for analysis of their data. The Medical Ethical Committee 
Brabant approved the SIMcal study.
2.2 | Data collection
The development, ongoing management and technical data-
base structure of the ESID online database were described 
previously.18 All participating centres entered their data in 
the study questionnaire, providing available demographic 
and clinical data (gender, date of birth, country of residence, 
age at diagnosis, date of diagnosis, presenting history, con-
ditions during follow‐up, pathogens, familial cases, con-
sanguinity), as well as laboratory test results (serum IgM, 
IgG, IgA and IgE levels, IgG subclasses, T cell subsets and 
function, antibody responses to vaccinations, isohemagglu-
tinin levels, anti‐nuclear antibodies (ANA) and specific IgE 
directed against inhalant allergens), treatment (antibiotics, 
immunoglobulin substitution) and follow‐up period (date 
of the first serum sample with decreased IgM until the date 
of data extraction). The answers to the questionnaires were 
encrypted and saved on a protected server using Research 
Manager software developed by Cloud9 Health Solutions 
(Deventer, the Netherlands). For interpretation of serum im-
munoglobulin levels, centre‐specific age‐matched reference 
values were used. Almost all centres used immunonephelo-
metric or immunoturbidimetric techniques (14 out of 15); in 
one centre, radial immunodiffusion was used (Egypt). The 
method of data collection for the 42 adults with true or pos-
sible sIgMdef from the secondary centre has been described 
before.15
2.3 | Statistical analysis
Frequency data were analysed with chi‐square analysis, 
and the Fisher exact test when expected cell values were 
lower than 5. Measurement data were expressed as means 
with standard deviations (SD) and confidence intervals (CI). 
Differences in measurements were tested with t test (Welch's 
t test when the variances are unequal) and ANOVA. The sta-
tistical software package used was IBM SPSS statistics ver-
sion 24.
3 |  RESULTS
Data from 98 patients were reported from 15 centres in 12 dif-
ferent countries. Thirty‐seven patients (37%) were excluded: 
14 because serum IgM level was only determined once, 8 be-
cause serum IgM level had normalized, and 15 because other 
immunological abnmalities were also present (these patients 
fulfilled the criteria for unPAD).
Of the remaining 61 patients, only 10 fulfilled the ESID 
criteria for true sIgMdef (5 adults, 5 children), and 51 had 
possible sIgMdef (8 adults, 43 children) when using the 
age‐matched cut‐off values for serum IgM used by the re-
porting centre. In those with possible sIgMdef, the following 
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immunological laboratory investigations were not deter-
mined: pneumococcal vaccination responses (0 adults and 
20 children), IgG subclasses (1 adult, 0 children) or both (7 
adults and 23 children). Cut‐off values varied widely between 
centres (Figure 1). When ESID diagnostic protocol cut‐off 
values for serum IgM were used,19 only 6 patients (5 adults, 1 
child) had true sIgMdef, and 8 had possible sIgMdef (6 adults 
and 2 children).
3.1 | Children
Analyses were done for the total group of children with 
possible or true primary sIgMdef (n = 48). Most children 
were reported from Turkey (n = 24), followed by Italy 
(n = 11), Tunisia (n = 4), Belgium (n = 3), Iran (n = 3), 
the Netherlands (n = 1) and Spain (n = 2). The mean age 
at the date of the first serum sample with decreased serum 
IgM in this possible/true sIgMdef cohort was 7 years (range 
0‐17 years). Mean follow‐up time was 54 months (range 
0‐162 months). Boys predominated (79%), but there was a 
significant association between country and gender (Fisher's 
exact test, two‐sided, P = 0.002). The numbers of children 
in the various countries were too small to draw reliable con-
clusions from the gender data (Figure 2). Consanguinity was 
present in six patients (13%, n = 2 male), absent in 39 (81%, 
n = 35 male) and not reported in three (6%, n = 1 male). 
These patients from consanguineous families were reported 
by Iran (2 out of 3), Italy (2 out of 11) and Turkey (2 out of 
24). Familial cases were present in three patients (6%; 2 from 
Iran, 1 from Italy), absent in 42 (81%) and not reported in 
three (6%).
Recurrent respiratory infections were the most commonly 
reported manifestation (n = 29; 60%). Other infectious man-
ifestations included mycobacterial adenitis, skin infections 
and bilateral pneumonia with an abscess. Atopic manifesta-
tions occurred in 11 children (21%), including eczema, food 
allergy and asthma. An autoimmune manifestation occurred 
in 1 child (2%), more specific information was not available 
in the database. The first serum IgM level ranged from 0.12 
to 0.62 g/L (mean 0.35 g/L). In the majority of the children, 
IgM levels were not decreased according to the ESID diag-
nostic protocol values; none had undetectable levels of serum 
IgM (Figure 3A). Analysis of variance showed a significant 
effect for differences in serum IgM levels between coun-
tries (F = 5.858, P = 0.001, partial η2 = 0.417, Figure 3B). 
Especially in Belgium, serum IgM values were higher and in 
Tunisia and Iran lower, but due to the low number of patients 
reported by these countries, it is difficult to interpret these 
results. Mean serum IgM levels were higher in males than 
in females (mean 0.37 versus 0.26 g/L; t(12.208) = 2.697, 
P = 0.02), but when the variation between countries was 
taken into account, this difference was no longer signifi-
cant (two‐way ANOVA; F(1,37) = 2.038, P = 0.1). Serum 
IgE levels were determined in 25 children (mean 184 U/mL, 
range 3‐1225); they were elevated (>90 U/mL) in 11 children 
(44%). Specific IgE to ≥1 inhalant allergen were positive in 
8/16 children (50%). Isohemagglutinin titres (anti‐A and an-
ti‐B antibodies in the IgM class) were determined in 23 chil-
dren, and low in two. Lymphocyte subsets were performed 
in 30 children (Table 1A). Three children (6%) were treated 
F I G U R E  1  Centre‐specific age‐matched cut‐off values of serum 
IgM (g/L). Each line represents the lower limit of normal for serum 
IgM used by a centre. The grey area represents serum IgM levels which 
are decreased according to the ESID diagnostic protocol values.19 The 
first serum IgM levels of the ten patients with true sIgMdef according 
to centre‐specific cut‐off values are plotted (C1,2,4 from Belgium; 
C3 from Iran; C5, A3 from the Netherlands; A1,2,4,5 from the Czech 
Republic). Of these, four patients were excluded when ESID diagnostic 
protocol values were used (shown in grey). ESID, European Society for 
Immunodeficiencies; sIgMdef, selective IgM deficiency
F I G U R E  2  Gender distribution per age group in the patients 
with possible and true sIgMdef. Light grey, male; dark grey, female. 
The number of children reported per country is shown for the male 
children. T, Turkey; Tu, Tunisia; I, Italy; B, Belgium; Ir, Iran; S, Spain; 
N, The Netherlands
4 of 10 |   JANSSEN Et Al.
with intravenous immunoglobulins (IVIG), and 10 (21%) 
with prophylactic antibiotics.
Clinical manifestations of the children with true sIgMdef 
are described separately in Table 1B (see Table S1 for more 
details on all the children, and Table S2 for a comparison 
between the Turkish children (largest group) and the children 
from the other countries).
3.2 | Adults
Thirteen adults (7 males) with true or possible sIgMdef were 
reported from Turkey (n = 4), Czech Republic (n = 4), the 
Netherlands (n = 3) and the United Kingdom (n = 2). The 
mean age at the date of the first serum sample with decreased 
IgM was 40 years (range 21‐63 years). Mean follow‐up time 
was 64 months (range 4‐144 months). None of the adults had 
a family history of immunodeficiency (unknown in one) or 
consanguinity.
Clinical manifestations of the adults with true sIgMdef are 
described in Table 2A (for details on all the adults, see Table 
S1). Increased susceptibility to infections, especially involv-
ing the respiratory tract, occurred most often (n = 7). Other 
reported infectious manifestations included hepatitis B, me-
ningococcal sepsis and recurrent herpes simplex virus (HSV) 
encephalitis. Atopic manifestations occurred in two adults, 
including atopic dermatitis and allergic rhinitis. Autoimmune 
manifestations occurred in three (Sjögren's disease, alopecia, 
coeliac disease). The first serum IgM level ranged from 0.10 
to 0.62 g/L (mean 0.27 g/L). Serum IgE levels were deter-
mined in five adults (mean 109 U/mL, range 4‐410); they 
were elevated (>90 U/mL) in two. Isohemagglutinin titres 
were determined in four adults, and low in one. Lymphocyte 
subsets were performed in nine patients (Table 2B), all fell 
within the normal range. None of the adults were treated 
with IVIG, and three (23%) were treated with prophylactic 
antibiotics.
3.3 | Comparison between the tertiary and 
secondary centre cohorts of adult patients
We first compared the 13 adults with true or possible sIgM-
def from this tertiary centre cohort with the 42 adults with 
true or possible sIgMdef from the secondary centre cohort 
we previously published.15 These two cohorts differ in the 
type of population from which the data were collected (gen-
eral hospital versus specialised medical centres) and in the 
way of collecting the data (analysing all laboratory data with 
decreased serum IgM vs only analysing patients reported as 
diagnosed with IgM deficiency by an immunologist). Given 
this different patient selection process, further immuno-
logical analyses were as expected more often performed in 
the tertiary centre cohort: repeated measurements of serum 
IgM in 86% vs 14% (Fisher's exact test, P < 0.001), meas-
urements of IgG subclasses in 92% vs 14% (Fisher's exact 
test, P < 0.001) and pneumococcal vaccination responses 
in 42% vs 7% (Fisher's exact test, P = 0.003). Not only in 
the previously described secondary centre cohort, but also 
in this tertiary centre cohort, few patients can be classified 
as true sIgMdef (Figure 4). In contrast to the tertiary cen-
tre cohort, adults in the secondary centre cohort were often 
asymptomatic. The first serum IgM levels were significantly 
higher in the secondary centre cohort (mean 0.30 g/L, 95% 
CI 0.28‐0.33) compared to the tertiary centre cohort (mean 
0.27 g/L, 95% CI 0.17‐0.37, P = 0.01; Figure 5A).
Second, comparisons were made between three groups: 
(a) symptomatic adults from the tertiary centres (n = 13), 
(b) symptomatic adults from the secondary centre (n = 18) 
F I G U R E  3  First serum IgM levels in the children from the 
tertiary centre cohort. A. The first serum IgM levels (y‐axis) and age at 
the date of the first serum sample (x‐axis). The grey dots represent the 
five children with true sIgMdef, and the red dots the 43 children with 
possible sIgMdef. The grey area in the graph represents decreased IgM 
levels according to the ESID diagnostic protocol values [18]. B. Mean 
first serum IgM levels + 95% CI in the different countries. sIgMdef, 
selective IgM deficiency
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T A B L E  1  Children. A, Lymphocyte subsets in children with true (n = 5) or possible sIgMdef (n = 25). B, Clinical manifestations of the 
children with true sIgMdef (n = 5)
Patient
Agea 
(years)
CD3 + T 
cells 
×10e9/L %
CD4 + T 
cells 
×10e9/L %
CD8 + T 
cells 
×10e9/L %
CD19 + B 
cells 
×10e9/L %
CD3‐
CD16 + CD56+ 
NK cells ×10e9/L %
A
True 
sIgMdef
C1 0b 2.5 1.2 1.2 0.7 0.2
C2 1 3.8 2.4 1.3 2 0.4
C3 4 45 33 11 33 17
C4 4 1.8 0.9 0.8 0.7 0.24
C5 11 1.6 0.8 0.6 NA NA
Possible 
sIgMdef
C6 0c 70 25 42 24 7
C7 0d 64 36 24 28 8
C9 1 67 39 25 21 7
C10 2 58 28 22 21 15
C13 4 1.9 1.0 0.8 0.2 0.2
C17 5 75 53 21 15 9
C18 5 72 47 23 22 5
C20 5 63 38 21 16 16
C22 5 90 52 38 3 11
C23 5 81 49 26 13 6
C26 6 75 30 34 13 10
C28 6 75 31 38 14 7
C29 7 1.9 1.0 0.7 0.5 0.36
C31 8 78 58 17 9 12
C32 8 73 36 34 15 10
C33 8 79 39 34 11 9
C34 9 57 35 12 13 24
C36 10 80 51 25 12 8
C37 10 58 26 30 16 18
C38 10 73 43 27 15 12
C39 10 68 43 23 16 14
C40 11 73 31 29 17 10
C41 11 73 38 17 7 16
C47 15 76 30 43 9 15
C48 17 77 39 29 7 15
Patient
Agea (years)/
gender Clinical manifestations
Familial 
cases
First and last 
serum IgM 
(g/L) Treatment
Follow‐up 
period (months)
B
C1 0/M Recurrent pneumonia No 0.62e , 0.39 IVIG + AB 105
C2 1/M Recurrent ENT infections n.r 0.45, 0.22 AB 30
(Continues)
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T A B L E  2  Adults. A, Clinical manifestations of the adults with true sIgMdef (n = 5). B, Lymphocyte subsets in adults with true (n = 5) or 
possible sIgMdef (n = 4)
Patient
Agea 
(years)/
gender Clinical manifestations
Familial 
cases
First and last  
serum IgM (g/l) Treatment
Follow‐up 
period (months)
A
A1 36/F Atopic dermatitis, allergic rhinitis, sinusitis No 0.10, 0.10 None 38
A2 38/F Bronchitis, nasopharyngitis, chronic hepatitis B No 0.14, 0.12 None 70
A3 50/F Bronchiectasis, coeliac disease, fatigue, 
recurrent respiratory infections
No 0.20, 0.37 AB 67
A4 55/M Vertebral pain syndrome No 0.10, 0.10 None 39
A5 63/F Sjögren's syndrome, alopecia, multiple lung 
cysts, fatigue
No 0.16, 0.14 None 101
Patient
CD3+T 
cells 
×10e9/L %
CD4+T 
cells 
×10e9/L %
CD8+T 
cells 
×10e9/L %
CD19+B 
cells 
×10e9/L %
CD3‐CD16+CD56+ 
NK cells ×10e9/L %
B
True 
sIgMdef
A1 0.9 0.6 0.3 0.2 0.12
A2 1.3 0.9 0.4 0.4 0.68
A3 2.0 1.5 0.6 0.1 0.20
A4 1.7 1.0 0.6 0.6 0.22
A5 0.8 0.5 0.3 0.3 0.19
Possible 
sIgMdef
A7 70 39 27 13 13
A10 2.0 0.9 1.0 0.2 0.10
A12 79 47 29 10 10
A13 1.3 0.9 0.4 0.1 0.12
Reference ranges from: Schatorjé et al Scand J Immunol 2011;74(5):502‐10.35
A, adult; AB, prophylactic antibiotics; F, female; IgM, immunoglobulin M; M, male; sIgMdef, selective IgM deficiency.
aAge at first sample collection. 
Patient
Agea (years)/
gender Clinical manifestations
Familial 
cases
First and last 
serum IgM 
(g/L) Treatment
Follow‐up 
period (months)
C3 4/F Complicated atypical mycobacterial 
adenitis, recurrent respiratory 
infections
Yes 0.17, 0.10 AB 42
C4 4/F Atopic dermatitis, eczema, food 
allergy, asthma, warts
No 0.38, 0.38 IVIG n.r
C5 11/F Severe eczema n.r n.r, 0.38 none 162
Reference ranges from: Schatorjé et al Scand J Immunol 2011;74(5):502‐10.35
AB, prophylactic antibiotics; C, child; ENT, ear‐nose‐throat; F, female; IgM, immunoglobulin M; IVIG, intravenous immunoglobulins; M, male; n.r, not reported; sIg-
Mdef, selective IgM deficiency.
aAge at first sample collection. 
b8 months. 
c6 months. 
d7 months. 
eThis serum IgM level is decreased according to the age‐matched reference values used by this centre. 
T A B L E  1  (Continued)
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and (c) asymptomatic adults from the secondary centre 
(n = 24) (Table 3). The mean age at diagnosis was sig-
nificantly higher in patients without symptoms that could 
be related to antibody deficiency (mean 65 years, 95% CI 
60‐70) compared to those with symptoms from the sec-
ondary centre (mean 56 years, 95% CI 49‐64) and tertiary 
centres (mean 40 years, 95% CI 31‐49; P < 0.01). We 
evaluated the mean first serum IgM levels in the different 
clinical manifestations (Figure 5B). Two symptoms, au-
toimmunity and fatigue, showed a significant difference, 
the patients with the symptoms having lower IgM levels 
(autoimmunity n = 6, mean 0.21 g/L, 95% CI 0.09‐0.33; no 
autoimmunity n = 49, mean 0.30 g/L, 95% CI 0.27‐0.33; 
t(53) = −2.137, P = 0.037; fatigue n = 9, mean 0.22 g/L, 
95% CI 0.16‐0.29; no fatigue n = 46, mean 0.31 g/L, 95% 
CI 0.27‐0.34; t(53) = −2.265, P = 0.03). When combining 
all symptoms that could be related to antibody deficiency, 
adults with these symptoms (n = 31) had significantly 
lower IgM levels compared to adults without these symp-
toms (n = 24) (mean 0.27 g/L, 95% CI 0.22‐0.31 vs mean 
0.33 g/L, 95% CI 0.30‐0.36; t(47.094) = 2.353, P = 0.02, 
Figure 5C).
F I G U R E  4  Classification of patients with decreased serum IgM in the tertiary (n = 98) and secondary (n = 359) centre cohorts. 
Abbreviations: sIgMdef, selective IgM deficiency; unPAD, unclassified primary antibody deficiency
F I G U R E  5  First serum IgM levels in 
the adults from the tertiary and secondary 
centre cohorts. Tertiary centre cohort 
n = 13, blue; secondary centre cohort 
n = 42, yellow. The first serum IgM 
levels (y‐axis) and age at the date of first 
serum sample (x‐axis) (A). The grey area 
in the graph represents decreased IgM 
levels according to the ESID diagnostic 
protocol values [18]. Mean first serum 
IgM levels + 95% CI (g/L) in the different 
clinical manifestations of adults from both 
tertiary and secondary centres (B), and in 
those with (n = 30) and without (n = 25) 
symptoms that could be related to antibody 
deficiency (C). *Two‐sided t test; P < 0.05
8 of 10 |   JANSSEN Et Al.
4 |  DISCUSSION
When isolated decreased serum IgM levels are repeatedly 
found in a patient, clinicians are confronted with a dilemma. 
To date, it is not clear what the clinical consequences of such 
a finding are, and whether and if so how such patients should 
be treated. The results of our study underline these chal-
lenges. Not only in our previously published secondary cen-
tre cohort,15 but also in this tertiary centre cohort as well as 
in other cohorts in the literature,5-7,14 only few patients with 
decreased serum IgM levels have true sIgMdef. This condi-
tion is probably very rare.
However, the adults with more severely decreased serum 
IgM levels were more likely to be younger and to be symp-
tomatic. This information can help in interpreting the clini-
cal significance when an isolated decreased serum IgM level 
is discovered. While just below normal values tend to have 
little clinical meaning, we suggest that lower cut‐off values 
than the current “two standard deviations (SD) below the 
mean” probably distinguish the clinically relevant category 
of patients. We propose to develop a classification for sIgM-
def similar to the one previously developed for selective IgA 
deficiency. This classification distinguishes selective IgA 
deficiency (serum IgA < 0.07 g/L) from the often clinically 
irrelevant partial IgA deficiency (serum IgA > 0.07 g/L but 2 
SD below normal age‐adjusted means).20,21 For selective IgM 
deficiency, such a cut‐off value will have to be determined in 
future studies.
Our study has several limitations. First, our results are 
based on a still relatively small cohort including not only true 
but also possible sIgMdef. This group contained a high num-
ber of children, which is in contrast to few children reported 
in the literature.5 This is probably bias resulting from the type 
of centres that decided to participate in the study. Second, it 
is possible that mildly affected patients with a known genetic 
defect are “hidden” in the sIgMdef population and fulfil the 
criteria for syndromic immunodeficiencies instead.22,23 This 
can only be revealed by genetic testing in such cases. Third, 
age‐matched cut‐off values varied widely between the cen-
tres; when using the ESID diagnostic protocol values, even 
fewer patients had true sIgMdef (1 child, 5 adults). This can-
not only be explained by variations in technique or in genetic, 
ethnic or geographical differences, which have also been 
shown to influence serum IgM levels.26,27 Almost all centres 
(14 out of 15) used immunonephelometric or immunotur-
bidimetric techniques, which have been demonstrated to be 
reliable and to have good comparability.33,34 Although inter‐
laboratory variability in the current methodologies can make 
T A B L E  3  Clinical and laboratory features of the adults with true or possible sIgMdef
Tertiary centre 
symptomatic (n = 13)
Secondary centre 
symptomatic (n = 18)
Secondary centre 
asymptomatica (n = 24) P value
Ageb , years (95% CI) 40 (31‐49) 56 (49‐64) 65 (60‐70) <0.01* 
Males, n (%) 7 (54) 11 (61) 12 (50) 0.79# 
Follow‐up period, months (95% CI) 64 (36‐92) 68 (52‐84) 80 (65‐95) 0.41* 
Clinical manifestation(s), n (%)
Infectious manifestations 7 (54) 9 (50) 0 (0) <0.01# 
Atopic manifestations 2 (15) 5 (28) 0 (0) 0.02# 
Autoimmune manifestation 3 (23) 1 (6) 0 (0) 0.05# 
Gastrointestinal disease 2 (15) 2 (11) 3 (12) 1.00# 
Long‐lasting fatigue 3 (23) 5 (28) 1 (4) 0.09# 
First IG levels, g/L (95% CI)
Serum IgM 0.27 (0.17 ‐ 0.37) 0.27 (0.22‐0.31) 0.33 (0.30‐0.36) 0.11* 
Serum IgG 12.1 (11.5‐13.6) 10.5 (9.5‐11.4) 10.7 (9.9‐11.5) 0.09* 
Serum IgA 2.4 (1.8‐3.0) 2.7 (1.9‐3.5) 2.9 (2.2‐3.6) 0.63* 
Treatment, n (%)c 
Prophylactic antibiotics 3 (23) 0 (0) 0 (0) 0.01# 
Tertiary centre cohort (n = 13), and symptomatic (n = 18) and asymptomatic (n = 24) secondary centre cohort.
CI, confidence interval; IG, immunoglobulin.
aThis means no symptoms potentially related to antibody deficiency were present. 
bAge at first sample collection. 
cNone of the adults were treated with immunoglobulins. 
*ANOVA. 
#Fisher's exact test. 
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unification of reference values challenging, investigating op-
portunities for achieving this would be worthwhile.
In conclusion, even this multi‐centre study could not solve 
the dilemma. Even enlarging the study to global proportions 
will probably not answer our questions. To be able to explore 
the clinical consequences of true sIgMdef, full analysis and 
accurate description of all patients in whom a decreased 
serum IgM is found would be more effective, leaving no pa-
tients with possible sIgMdef to dilute the results.
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